An Early Phase 1 interventional study of Cannabidiol supplement in Diet Modification, sponsored by University of British Columbia. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-23.
Sponsored by University of British Columbia · Early Phase 1, Interventional, and Basic science
Cannabidiol (CBD) is a bioactive cannabinoid compound in marijuana (cannabis sativa), but unlike Δ9 tetrahydrocannabinol (THC), lacks the psychoactivity effect of THC. Available evidence suggests that there are marked therapeutic CBD effects for diverse disease processes including inflammation, cancers, psychosis, and epileptic seizures. The purpose of this study, in both younger and older healthy humans, is to improve our understanding of how CBD might control and regulate blood vessel health as well as cognitive and exercise performance.
Exclusion Criteria:
Sugar pill that will have no effect.
Dietary Supplement: Cannabidiol supplement
Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
Dietary Supplement: Cannabidiol supplement
Only cannabidiol supplement.
Dietary Supplement: Cannabidiol supplement
Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
Dietary Supplement: Cannabidiol supplement
Only cannabidiol supplement.
Dietary Supplement: Cannabidiol supplement
Subjects will be administered in a double-blinded, randomized and cross-over design
Circulating cannabidiol and nitric oxide markers
Measured by venous blood sampling
Time frame: Through study completion, an average of 1 year
Vascular function
Duplex ultrasound system
Time frame: Through study completion, an average of 1 year
Height
Height in cm
Time frame: Through study completion, an average of 1 year
Weight
Weight in kg
Time frame: Through study completion, an average of 1 year
Body mass index
Body mass in kilograms divided by height in meters squared
Time frame: Through study completion, an average of 1 year
Systolic blood pressure
Measured by automated sphygmomanometer
Time frame: Through study completion, an average of 1 year
Diastolic blood pressure
Measured by automated sphygmomanometer
Time frame: Through study completion, an average of 1 year
Heart rate
Measured by 3-lead electrocardiogram
Time frame: Through study completion, an average of 1 year
Respiration
Measured by spirometry
Time frame: Through study completion, an average of 1 year
Medical History Questionnaire
Assesses inclusion/exclusion criteria and prior history of medical conditions.
Time frame: Through study completion, an average of 1 year
Gastrointestinal Distress Questionnaire
Measured using a 10 cm visual analogue scale
Time frame: Through study completion, an average of 1 year
Anxiety Questionnaire
Assessed with a visual analog scale
Time frame: Through study completion, an average of 1 year
Cognitive performance
Computerized battery of neuropsychological tests
Time frame: Through study completion, an average of 1 year
Exercise performance
Step-wise exercise test on cycle ergometer
Time frame: Through study completion, an average of 1 year
Plan to share: No — Individual values will be reported in figures if applicable.
This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia